nice_老虎社区_美港股上老虎

keatwong
2021-10-01

nice

Nutriband Inc. Prices $6.6 million Public Offering and Announces Uplisting to the NASDAQ Capital Market

ORLANDO, FL / ACCESSWIRE / October 1, 2021 / Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), a compan

Nutriband Inc. Prices $6.6 million Public Offering and Announces Uplisting to the NASDAQ Capital Market

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":864682206,"tweetId":"864682206","gmtCreate":1633097840798,"gmtModify":1633097841029,"author":{"id":3575785607031015,"idStr":"3575785607031015","authorId":3575785607031015,"authorIdStr":"3575785607031015","name":"keatwong","avatar":"https://static.tigerbbs.com/b440c303dc2a35e0a2c45f896a7d779f","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":11,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>nice</p></body></html>","htmlText":"<html><head></head><body><p>nice</p></body></html>","text":"nice","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/864682206","repostId":2172968717,"repostType":4,"repost":{"id":"2172968717","kind":"news","pubTimestamp":1633095960,"share":"https://ttm.financial/m/news/2172968717?lang=&edition=full","pubTime":"2021-10-01 21:46","market":"us","language":"en","title":"Nutriband Inc. Prices $6.6 million Public Offering and Announces Uplisting to the NASDAQ Capital Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2172968717","media":"StreetInsider","summary":"ORLANDO, FL / ACCESSWIRE / October 1, 2021 / Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), a compan","content":"<p><b>ORLANDO, FL / ACCESSWIRE / October 1, 2021 / Nutriband Inc. </b>(NASDAQ: NTRB) (NASDAQ: NTRBW), a company engaged in the development of pharmaceutical products focused on preventing opioid abuse, contract research and development services and the contract manufacturing of topical and transdermal products, today announced that its common stock and warrants will begin trading on the Nasdaq Capital Market effective October 1, 2021.</p>\n<p>Nutriband also announced the pricing of an underwritten public offering of 1,056,000 units of securities at a public offering price of $6.25 per unit for total gross proceeds of $6.6 million, before deducting underwriting discounts and commissions and other estimated offering expenses. Each unit consists of <a href=\"https://laohu8.com/S/AONE.U\">one</a> share of common stock and one warrant. Each warrant is immediately exercisable, will entitle the holder to purchase one share of common stock at an exercise price of $7.50 and will expire five years from the date of issuance. The shares of common stock and Warrants may be transferred separately immediately upon issuance. In addition, Nutriband Inc. has granted the underwriters a 45-day option to purchase up to 158,400 additional shares of common stock and 158,400 additional warrants to cover over-allotments in this offering.</p>\n<p>\"Uplisting onto the Nasdaq Capital Market is a significant milestone in our evolution, and we believe will exponentially increase our corporate visibility and broaden the awareness of Nutriband amongst active market participants,\" said Gareth Sheridan, CEO. \"This achievement reflects the hard work of our outstanding team, and we look forward to continuing to execute on our strategic plan and growth initiatives as we build long term shareholder value.\"</p>\n<p>The shares and warrants will begin trading on The Nasdaq Capital Market effective Friday, October 1, 2021, under the symbols \"NTRB\" and \"NTRBW\", respectively.</p>\n<p>WallachBeth Capital, LLC and WestPark Capital, Inc acted as the joint book-running managers for the offering.</p>\n<p><b>About Nutriband Inc.</b></p>\n<p>We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA technology. Aversa is an abuse deterrent transdermal technology that incorporates aversive agents to prevent the abuse, diversion, misuse and accidental exposure of drugs with abuse potential, specifically opioids.</p>\n<p>The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.</p>\n<p><b>About Our Forward-Looking Statements</b></p>\n<p>Certain statements contained in this press release, including, without limitation, statements containing the words 'believes,'' \"anticipates,\" \"expects\" and words of similar import, constitute \"forward-looking statements\" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under \"Risk Factors\" and \"Management's Discussion and Analysis of Financial Condition and Results of Operations\" in the Company's Form S-1, Form 10-K for the year ended January 31, 2020 and Forms 10-Q, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.</p>\n<p>For more information, contact:Gerald WeigelPublic Relations PrincipalNutriband Inc.Nutriband Office: 407-377-6695Direct: 419-304-6300</p>\n<p><b>SOURCE:</b> Nutriband Inc.</p>\n<p></p>\n<p></p>\n<p>View source version on accesswire.com:</p>\n<p>https://www.accesswire.com/666396/Nutriband-Inc-Prices-66-million-Public-Offering-and-Announces-Uplisting-to-the-NASDAQ-Capital-Market</p>\n<p></p>\n<p><img src=\"https://static.tigerbbs.com/db04c7b378cb2db912c3ba8a5a774ee3\" tg-width=\"1\" tg-height=\"1\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nutriband Inc. Prices $6.6 million Public Offering and Announces Uplisting to the NASDAQ Capital Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNutriband Inc. Prices $6.6 million Public Offering and Announces Uplisting to the NASDAQ Capital Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-01 21:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19011036><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ORLANDO, FL / ACCESSWIRE / October 1, 2021 / Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), a company engaged in the development of pharmaceutical products focused on preventing opioid abuse, contract...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19011036\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OLPX":"Olaplex Holdings, Inc.","FWRG":"First Watch Restaurant Group, Inc.","NTRB":"Nutriband Inc.","CRCT":"Cricut, Inc.","HCTI":"Healthcare Triangle, Inc.","TERN":"Terns Pharmaceuticals, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19011036","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2172968717","content_text":"ORLANDO, FL / ACCESSWIRE / October 1, 2021 / Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), a company engaged in the development of pharmaceutical products focused on preventing opioid abuse, contract research and development services and the contract manufacturing of topical and transdermal products, today announced that its common stock and warrants will begin trading on the Nasdaq Capital Market effective October 1, 2021.\nNutriband also announced the pricing of an underwritten public offering of 1,056,000 units of securities at a public offering price of $6.25 per unit for total gross proceeds of $6.6 million, before deducting underwriting discounts and commissions and other estimated offering expenses. Each unit consists of one share of common stock and one warrant. Each warrant is immediately exercisable, will entitle the holder to purchase one share of common stock at an exercise price of $7.50 and will expire five years from the date of issuance. The shares of common stock and Warrants may be transferred separately immediately upon issuance. In addition, Nutriband Inc. has granted the underwriters a 45-day option to purchase up to 158,400 additional shares of common stock and 158,400 additional warrants to cover over-allotments in this offering.\n\"Uplisting onto the Nasdaq Capital Market is a significant milestone in our evolution, and we believe will exponentially increase our corporate visibility and broaden the awareness of Nutriband amongst active market participants,\" said Gareth Sheridan, CEO. \"This achievement reflects the hard work of our outstanding team, and we look forward to continuing to execute on our strategic plan and growth initiatives as we build long term shareholder value.\"\nThe shares and warrants will begin trading on The Nasdaq Capital Market effective Friday, October 1, 2021, under the symbols \"NTRB\" and \"NTRBW\", respectively.\nWallachBeth Capital, LLC and WestPark Capital, Inc acted as the joint book-running managers for the offering.\nAbout Nutriband Inc.\nWe are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA technology. Aversa is an abuse deterrent transdermal technology that incorporates aversive agents to prevent the abuse, diversion, misuse and accidental exposure of drugs with abuse potential, specifically opioids.\nThe Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.\nAbout Our Forward-Looking Statements\nCertain statements contained in this press release, including, without limitation, statements containing the words 'believes,'' \"anticipates,\" \"expects\" and words of similar import, constitute \"forward-looking statements\" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under \"Risk Factors\" and \"Management's Discussion and Analysis of Financial Condition and Results of Operations\" in the Company's Form S-1, Form 10-K for the year ended January 31, 2020 and Forms 10-Q, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.\nFor more information, contact:Gerald WeigelPublic Relations PrincipalNutriband Inc.Nutriband Office: 407-377-6695Direct: 419-304-6300\nSOURCE: Nutriband Inc.\n\n\nView source version on accesswire.com:\nhttps://www.accesswire.com/666396/Nutriband-Inc-Prices-66-million-Public-Offering-and-Announces-Uplisting-to-the-NASDAQ-Capital-Market","news_type":1,"symbols_score_info":{"ALVU":0.9,"CRCT":0.9,"FWRG":0.9,"HCTI":0.9,"NTRB":0.9,"OLPX":0.9,"TERN":0.9}},"isVote":1,"tweetType":1,"viewCount":2721,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Nutriband Inc. Prices $6.6 million Public Offering and Announces Uplisting to the NASDAQ Capital Market

评论（3）

热议股票